Agoracom Blog Home

Posts Tagged ‘weed’

#Marijuana’s Biggest Day of the Year Is 4 Weeks Away! – SPONSOR: #NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 11:55 AM on Thursday, September 19th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

—————————————————–

Marijuana’s Biggest Day of the Year Is 4 Weeks Away

  • Last year, the marijuana industry made history… many times over.
  • But nothing took precedence over Canada becoming the first industrialized country in the world to legalize recreational cannabis, with sales commencing on Oct. 17, 2018.

Sean Williams Sep 19, 2019 at 6:06AM

Last year, the marijuana industry made history… many times over. But nothing took precedence over Canada becoming the first industrialized country in the world to legalize recreational cannabis, with sales commencing on Oct. 17, 2018. Even though Canada substantially trails the U.S. in terms of aggregate annual legal weed sales, it’s setting an example among industrialized countries that the legalization of marijuana is possible.

Now, the biggest date of 2019 is rapidly approaching. And wouldn’t you know it, it’s Oct. 17, once again.

Image source: Getty Images.

Why Oct. 17 is a big date for the pot industry (again)

Four weeks from today, laws governing the rollout of derivatives will officially go into effect in Canada. A derivative is an alternative cannabis consumption product that’s not already been approved.

Over the past 11 months and change, Canada has allowed for the sale of dried cannabis flower, cannabis oil, and sublingual sprays. Meanwhile, edibles, nonalcoholic cannabis-infused beverages, vapes, concentrates, and topicals, weren’t legal. This sort of two-step legalization process was done to allow the industry to find its footing, as well as give regulators time to adjust to cannabis becoming legal for adult purchase. But on Oct. 17, regulations now governing dried cannabis will apply to derivative products as well.

However, investors and Canadian consumers should understand that derivative pot products aren’t going to be showing up in dispensaries on Oct. 17. Much in the same way that it took dried cannabis flower brands weeks to begin populating dispensary store shelves, it’ll probably be the same story for derivative products. Regulatory agency Health Canada has cautioned that derivative supply won’t hit the market until mid-December, with it taking weeks or months thereafter for supply to be adequate to meet demand.

This, of course, is really big news for marijuana stocks, because derivative cannabis products are a considerably higher margin product for the industry, relative to dried flower. In select U.S. states (ahem, Oregon), we’ve witnessed the oversupply and commoditization of dried flower, leading to weaker margins for pot businesses. We’re highly unlikely to see oversupply and pricing concerns from derivatives anytime soon.

A point that is sometimes lost on this derivative launch is that these are products which speak to a younger generation of cannabis users. Not only are derivatives more attractive in the respect that they may not need to be smoked, but they’re going to attract potentially long-term customers to the industry.

Image source: Getty Images.

Growers go all-out for derivative production

Considering the importance of derivatives to cannabis stock margins, it’s not surprising to find that growers have been laser-focused on derivative production for a good portion of 2019.

Some growers, such as OrganiGram Holdings (NASDAQ:OGI), have chosen to set up a variety of in-house derivative options. During the company’s fiscal third quarter, OrganiGram announced that it’d be investing 15 million Canadian dollars into a line of fully automated equipment necessary to produce up to 4 million kilos of chocolate edibles per year. This coincides with OrganiGram’s 56,000-square-foot phase 5 expansion which, among other things, is targeted at extra space for derivative production and processing.

The company has also developed a nano-emulsification technology that can speed up the onset of the effects of cannabinoids. This product will first be introduced as a powder that can be added to beverages, but OrganiGram is also actively looking for a partner to help it develop an infused beverage product containing this proprietary technology.

Cronos Group (NASDAQ:CRON), and its investment partner Altria, are also eager to see the green flag wave on derivatives. Cronos Group’s peak annual output of nearly 120,000 kilos per year may not even be enough to place this brand-name pot stock among the top-10 growers. But that’s OK with Cronos, as it’s placed its attention almost entirely on derivative cannabis products.

For instance, Cronos and Altria will be working together to roll out an assortment of vape products. Altria is well-versed in the adult smoking market and should prove helpful in assisting Cronos Group’s marketing efforts and product launches (regarding vapes). Beyond vaping, Cronos Group will be leaning on its partnership with Ginkgo Bioworks to produce targeted cannabinoids at commercial scale, as well as other third-party extraction service providers.

Image source: Getty Images.

Speaking of extraction services, there may not be a smarter way of playing the derivatives craze than with third-party extraction providers. As an example, MediPharm Labs (OTC:MEDIF) only commenced its extraction operations during the fourth quarter. Despite this, MediPharm managed to turn a nominal operating profit of $0.01 per share in the second quarter. The company’s sales and profitability are set to soar as growers scramble for derivative exposure. Yet, MediPharm’s sales and profits should remain highly predictable with the company locking in contracts for an extended period of time. Soon enough, the company’s annual extraction capacity will hit 500,000 kilos.

The one thing to remember about the upcoming marijuana derivatives launch

While, on one hand, the launch of derivative products should be lauded by investors, there’s another side to this launch that everyone should be aware of.

As I alluded to earlier, Health Canada has cautioned that alternative consumption products aren’t going to immediately hit dispensary shelves once the green flag waves on Oct. 17. Rather, it’s going to take time before any sort of supply is built up in the marketplace, with a presumptive two-month gap between when derivative regulations going into effect and when derivative products will begin showing up in licensed stores.

But here’s the thing: Product showing up in stores doesn’t mean that the supply will be sufficient to meet demand. Similar to what we’ve been witnessing in the dried flower market, supply issues exist that are likely going to make it difficult for derivative products to find their way into dispensaries, at least in the early going.

Don’t get me wrong, I expect derivatives to push sales and margins higher for cannabis stocks across the board. However, I think it’s going to be multiple quarters before Health Canada resolves a number of supply issues, resulting in what could be weaker-than-expected sales in the months to come.

Make no mistake: Derivatives are the future of the cannabis industry. Just understand that the future isn’t going to happen overnight. Give this industry, and the rollout of derivatives, proper time to mature, and you won’t be disappointed.

Here’s The Marijuana Stock You’ve Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 10 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company…and you need to hear this story today if you have even considered investing in pot stocks.

Source: https://www.fool.com/investing/2019/09/19/marijuanas-biggest-day-of-the-year-is-4-weeks-away.aspx

Empower Clinics $CBDT.ca Announces Joint Venture with Heritage Cannabis for the Production of Hemp Derived #CBD Oils and Formulated Products in Oregon USA $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 7:55 AM on Tuesday, September 17th, 2019
  • Announced that it has entered into a Letter of Intent to form a Joint Venture Partnership with HERITAGE CANNABIS HOLDINGS CORP. (CSE: CANN) in Sandy, OR for the extraction of hemp for CBD oil production, and formulated CBD products
  • Heritage, via its wholly owned subsidiary Purefarma Solutions Inc., will install extraction units and related downstream extraction equipment inside Empower’s existing 5,000 sq. ft. licenced hemp processing facility in Sandy, OR.
  • JV will be equally funded by both companies with Heritage investing an initial $500,000 for start-up funds, as the build out completes and the JV secures high quality hemp supply from local growers.

VANCOUVER, Sept. 17, 2019 – EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, is pleased to announce that it has entered into a Letter of Intent (“LOI”) to form a Joint Venture Partnership (“JV”) with HERITAGE CANNABIS HOLDINGS CORP. (CSE: CANN) (“Heritage“) in Sandy, OR for the extraction of hemp for CBD oil production, and formulated CBD products.

Terms of the LOI have Empower and Heritage each with a 50% ownership of the JV. Heritage, via its wholly owned subsidiary Purefarma Solutions Inc. (“Purefarma”), will install extraction units and related downstream extraction equipment inside Empower’s existing 5,000 sq. ft. licenced hemp processing facility in Sandy, OR. In addition, Purefarma will train and supervise the staff on the proprietary methods of extraction and oil production that it produces in Canada. The JV will be equally funded by both companies with Heritage investing an initial $500,000 for start-up funds, as the build out completes and the JV secures high quality hemp supply from local growers.

Once operational, the JV will begin producing proprietary branded products for Empower’s corporately owned physician staffed health clinics in Washington State, Oregon, Nevada and Arizona. These clinics include Sun Valley Health (“Sun Valley”), a subsidiary of Empower, which has direct marketing access to over 165,000 patients and growing as Sun Valley expands its franchised network nationwide. The JV will utilize formulations from Heritage in Canada, as well as manufacture proprietary Sollievo branded products that Empower distributes throughout its clinic network.

“By moving forward with Heritage in this JV, it allows us to execute our growth strategy more quickly and efficiently. We will expand our clinics and CBD product offerings throughout the USA via our franchise model, as we aim to become a significant part of the cannabis wellness marketplace.” states Steven McAuley, Empower’s Chief Executive Officer.

The JV will also look to manufacture white label products for other distributors throughout the USA, and it is currently in talks with several potential customers to produce tinctures, topicals, gel caps and formulated bulk CBD oil.  

“This is a big step for Heritage as we expand our unique capabilities south of the border into the USA. We are fortunate to be working with Empower as they bring distribution, and a licensed facility which will allow us to begin immediately filling an order pipeline.” says Clint Sharples, CEO of Heritage “Since our 30% acquisition of Endocanna Health in California, they have introduced us to many quality opportunities, including this one with Empower, and are targeting many more in the future.”

Additional HIGHLIGHTS

  • Extraction Facility Progress The Company has been awarded its hemp-handlers license from the Oregon Department of Agriculture, and now are approved to operate the new 5,000 sq. ft. facility in Sandy, OR. Pathangay Architects have been retained to complete the design and drawings, to submit permit approvals that commence the next phase of build-out. Security systems and IT networks have been installed. The Company intends to include these assets as part of the JV.

  • Hemp Bio-Mass Supply The Company has commenced RFP’s (Request For Proposal’s) to access the more than 1,300 licensed hemp farmers in the State of Oregon, that are known to produce some of the highest quality hemp bio-mass in the United States.

  • CBD Market Demand The passing in the United States of the US$867 billion Agriculture Improvement Act (the “Farm Bill“) has legalized hemp and hemp-based products. This has created an opportunity for the production and sale of a variety of CBD-based products that can provide genuine help and effective relief to millions of people suffering from a variety of qualifying conditions. Recent reports and studies indicate the approval of the Farm Bill could create a US$23 billion industry by 2023

  • Sun Valley Health Franchise Sun Valley Health www.sunvalleyhealth.com offers a scientific approach to alternative medicine supported by a network of nine (9) corporate locations and a nationwide franchise program that offers a turnkey opportunity including:
  • An electronic medical system that handles patient data and sensitive information, and deals with program tracking, referrals, and appointment reminders
  • A proven operational system that has 165,000 patients in its database
  • A retail CBD and premium wellness product offer to diversify and attract customers
  • An industry leading campaign management system using text messaging, email and call center systems to engage patients and customers
  • Paperless communication channels that are HIPAA compliant
  • On-site and web-based training systems to develop franchisees
  • Sophisticated advertising programs proven to connect with local customers
  • Support and infrastructure to ensure franchisees have a formula for success

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

About Heritage Cannabis Holdings Corp.

The Company is a vertically integrated cannabis provider that currently has two Health Canada approved licenced producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licences, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and BriteLife Sciences that is focused on cannabis based medical solutions. Heritage as the parent Company, is focused on providing resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed JV and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation in 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed JV and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/17/c9158.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019

As Canada gears up for #pot 2.0, more shortages are on the menu, bodes well for #NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:04 PM on Monday, September 16th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

As Canada gears up for pot 2.0, more shortages are on the menu

  • Canada will add edibles, extracts and topicals to the list of legal cannabis products no later than Oct. 17.
  • Many analysts agree these products will generate better demand and margins than dried flower.
  • But the federal government has not yet issued regulations for the new formats, making it difficult for producers to prepare lest they unknowingly violate some rule.

By: Kristine Owram, Bloomberg News

Canada’s legalization of pot edibles later this year is facing an even more shambolic start than the dried flower market, which is still struggling to meet demand, according to industry players.

“At least that time we knew what the permissible product types were going to be and were already making them in the medical context,” said cannabis lawyer Trina Fraser, a partner at Brazeau Seller Law in Ottawa.

Canada will add edibles, extracts and topicals to the list of legal cannabis products no later than Oct. 17. Many analysts agree these products will generate better demand and margins than dried flower. But the federal government has not yet issued regulations for the new formats, making it difficult for producers to prepare lest they unknowingly violate some rule.

A spokeswoman for Health Canada declined to comment on when the regulations will be released.

In addition, a huge licensing backlog has built up at Health Canada, the government agency that oversees cannabis regulations. About 614 applications were waiting in the queue as of March 31.

“A full rollout amongst a nice wide array of producers and a wide array of these new product types is going to take time, literally years, because we have such a licensing backlog,” Fraser said.

Company Stockpiling

Canada’s market for edibles and other alternative pot produces will eventually be worth C$2.7 billion ($2 billion) annually, but consumers should expect “missteps, delays and frustration” in the early days, Deloitte said in a report published Monday. Jennifer Lee, Deloitte Canada’s cannabis national leader, estimated it will be a minimum of 24 months before the industry normalizes.

In the meantime, many pot companies are stockpiling, choosing to forgo revenue today to ensure they have enough supply for the new high-value products. This is exacerbating the shortage of dried flower, but executives say it’s worth it.

“We’ve made a very conscious effort to delay revenue,” said Chuck Rifici, chief executive officer of Auxly Cannabis Group Inc. Selling into the market today doesn’t build brand recognition because shelves are empty and consumers are buying whatever’s available, he added. “I would much rather save that product, get a multiple of margin on that brand and make sure that I have enough inventory.”

Lab Delays

This is proving to be a boon for extraction companies like Valens GroWorks Corp. Valens has contracts with many of the biggest pot companies, including Canopy Growth Corp., Hexo Corp. and Tilray Inc., to extract cannabis oil from their plants, which is then used for products like edibles and vape cartridges. It’s also investing heavily in its testing labs in the belief that Health Canada will have stringent regulations to ensure pesticides and other contaminants don’t make it into the new consumer products.

“Even in labs today there’s delays where people are waiting three weeks to a month to get lab results back and I think that will only get worse,” said Everett Knight, Valens’ executive vice president of strategy and investments.

Companies are also making big bets on what products will be in demand, with Canopy and Hexo leaning toward cannabis beverages and others toward vaping.

Be Prepared

“Why do I want an edible or a drink when I can have a vape?” Irwin Simon, interim CEO of Aphria Inc., said in an interview on the sidelines of a cannabis conference last month. “I see the margins and the opportunities there.”

Rifici at Auxly also believes vape pens will be “the most important category by far.” But there are many unanswered questions. For example, will the government require companies to engrave its mandatory THC warning symbol into the pen itself, or will a sticker suffice?

This is why Valens is offering its customers 196 different options for its white-label vape pens. “You’ve got to make sure you cover your bases and prepare for all the possibilities,” Knight said.

Despite the uncertainty, it’s better to be prepared even if plans and production lines have to be tweaked once the regulations come out, said Bruce Linton, CEO of Canopy, which is building a 197,000 square foot bottling plant for cannabis beverages in Smiths Falls, Ontario.

“We’re in a situation where it’s better to spend money to be ready than to save money and be late,” he said.

 Cannabis Canada is BNN Bloomberg’s in-depth series exploring the stunning formation of the entirely new – and controversial – Canadian recreational marijuana industry. Read more from the special series here and subscribe to our Cannabis Canada newsletter to have the latest marijuana news delivered directly to your inbox every day.

Source: https://www.bnnbloomberg.ca/as-canada-gears-up-for-pot-2-0-more-shortages-are-on-the-menu-1.1268844

Bougainville Ventures $BOG.ca Oroville Campus Tenant Receives Production Approval, Signals Major Company Milestone $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 7:50 AM on Friday, September 13th, 2019
  • licensed I-502 tenant-grower for the Company’s Oroville Campus has received their final production approval from the Washington State Liquor Control Board (WSLCB) to commence operations.
  • This signals a major milestone for the Company and its obligation to our tenant-grower for a turnkey facility and more importantly to begin cash flow as early as the first quarter of next year.
  • The first 10,000 sq. ft. of a 30,000 sq. ft. Tier-3, I-502 production and processing license is already built. In addition to the 10,000 sq .

Vancouver, British Columbia–(September 13, 2019) – BOUGAINVILLE VENTURES INC. (CSE: BOG) (OTC Pink: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Bougainville” or the “Company”) is pleased to announce that further to its news release on July 25, 2019, that the licensed I-502 tenant-grower for the Company’s Oroville Campus has received their final production approval from the Washington State Liquor Control Board (WSLCB) to commence operations. This signals a major milestone for the Company and its obligation to our tenant-grower for a turnkey facility and more importantly to begin cash flow as early as the first quarter of next year. The first 10,000 sq. ft. of a 30,000 sq. ft. Tier-3, I-502 production and processing license is already built. In addition to the 10,000 sq. The tenant is licensed to build out up to 30,000 sq. ft and once fully built-out the facility will be able to house 3,000 plants. Further updates will be provided as they are made available.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6334/47763_6271dd4f2451181b_001.jpg



Figure 1: Oroville Campus

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6334/47763_6271dd4f2451181b_001full.jpg

CEO, Andy Jagpal Comments:

“This is a major milestone as this was the project the company went public with and to see it come to fruition is a testament to the bougainville team and our relentless pursuit to follow through with our commitments.” To learn more about what this news means to the shareholders visit https://marketnewsfirst.com/bog-news, as well as on the company’s site.

About the Washington I-502 Marijuana Market

In November 2012, the Washington State Liquor Control Board (WSLCB) passed Initiative 502 (I-502) pursuant to a vote by the people of the State of Washington. I-502 authorized the WSLCB to regulate and tax recreational marijuana products for persons over twenty-one years of age and thereby created a new industry for growing, processing and selling of Washington State-regulated recreational marijuana products. A recent WSLCB commissioned report by the Rand organization suggests that there are currently up to 650,000 recreational marijuana users in Washington State, worth approximately $1.25 – $1.5 billion USD in annual sales.

About Bougainville Ventures, Inc.

Bougainville Ventures Inc. is dedicated to rapid growth in production, processing, retail and branding of cannabis and cannabis related products. Currently the company provides strategic capital to the thriving cannabis cultivation sector through ownership and development of commercial real estate properties. We offer fully built out turnkey facilities equipped with state-of-the-art growing infrastructure to cannabis growers and processors. Also, the Company is focused on building a strong presence in the hemp industry with the objective of extracting cannabinoids in both Canada and the United States. Along with our flagship Hemp project in Oregon State and the Greenhouse campus in Washington state, the Company has proprietary formulas for cannabis edibles, topical, and tinctures.

On behalf of the Board of Directors
BOUGAINVILLE VENTURES INC.

Andy Jagpal, President and Director

For further information, please contact Andy Jagpal at [email protected]. Please note that our Toll free number has changed to 1-877-517-7816.

http://bougainvilleinc.com/
https://twitter.com/bougainvilleinc

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

North Bud Farms $NBUD.ca Restructures Proposed California Operations with Signing of Offer to Purchase 11-Acre Property in Salinas, California $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 4:42 PM on Thursday, September 12th, 2019
  • Entered into a land purchase agreement with the Qlora Group to acquire a fully operational Cannabis farm consisting of approximately 300,000 sq. ft. of greenhouse capacity located in Salinas, California. 
  • With the near 11-acre cultivation facility comes additional licenses for processing and distribution. 
  • Transaction is valued at USD$11 million.       

TORONTO, Sept. 12, 2019 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company”) is pleased to announce that Bonfire Brands USA, a wholly owned subsidiary of NORTHBUD, has entered into a land purchase agreement with the Qlora Group to acquire a fully operational Cannabis farm consisting of approximately 300,000 sq. ft. of greenhouse capacity located in Salinas, California.  With the near 11-acre cultivation facility comes additional licenses for processing and distribution.  The transaction is valued at USD$11 million.       

The facility in Salinas, California is currently licensed and operating a 60,000 sq. ft. greenhouse capable of producing 12,000 kg a year and holds the approval to expand up to approximately 300,000 sq. ft. of capacity with estimated yields of 60,000 kg a year.  This infrastructure will serve as the primary operation for Bonfire Brands USA within the state of California, which is considered to be the largest cannabis market in the United States.

“Over the past seven months we have observed an evolution in the California market,” stated Justin Braune, President of Bonfire Brands USA. “Many existing legacy operations have been unsuccessful in transitioning their businesses into the adult use market post January 1st, 2019. Supply issues and licensing time frames have caused widespread re positioning of market shares amongst many verticals. Since the creation of Bonfire, we have determined that the acquisition of strategic licensed infrastructure will provide Bonfire with the most efficient operational structure possible. By controlling the complete vertical in one location per state we will have the capacity to increase both our offerings and margins. This will enable us to further improve our own brands as well as we work with complementary partners over a wide spectrum of product segments.”

Transaction Terms
Bonfire Brands USA entered into the land purchase agreement effective September 9, 2019.   The purchase price of the land is USD$8M. As part of the 60-day escrow agreement Bonfire Brands USA will make an initial deposit of USD$500,000. The remaining USD$7.5M mortgage will be held by the seller at a fixed interest rate. Over the first 12 months, Bonfire Brands USA will make interest only payments before entering into a traditional principal and interest mortgage. Upon successfully transferring all licenses from Monterey Holdings to Bonfire Brands USA, the Company will issue a convertible debt note in the amount of CAD$2.5M.  The debt note will be redeemable in four equal installments to be paid in cash or common shares of NORTHBUD (valued at the 30-day VWAP of the common shares on the CSE) at the discretion of the note holder.  If the note holder chooses to redeem in cash, then the installment will be paid in monthly installments over a 3-month period.  Any issuance of common shares of NORTHBUD will be subject to receipt of applicable regulatory approvals, including that of the CSE, and standard restrictions on resale.

Upon closing of the real estate transaction, it is expected that Bonfire Brands USA will begin to immediately operate the facilities under an operations agreement until the license transfer is complete.

In addition, Bonfire Brands USA intends to acquire the remaining assets of the Qlora Group related to the brands “California Bud Co.” and “Live For The Day” (LFTD) in exchange for common shares of NORTHBUD. Qlora Group advises that the brands accounted for USD$4.5M in unaudited revenue in 2018.  This transaction is expected to take approximately six months to complete for a consideration of USD$500,000. 

The Transaction is a significant acquisition but will not result in a “Fundamental Change” pursuant to the policies of the CSE. NORTHBUD will be preparing the necessary corporate and securities filings in order to secure the required approvals for the Transaction.

NORTHBUD has agreed to pay up to 5% in finder fees to arm’s length parties in connection with the closing of the Transaction. The fee is payable in common shares of NORTHBUD.

The closing of the Transaction is conditional on the receipt by the parties of applicable corporate and regulatory approvals including that of the CSE.

U.S. Expansion Update
NORTHBUD is pleased to have solidified its California expansion strategy with this this proposed transaction with Qlora Group and in light of this development and other factors  NORTHBUD has agreed to mutually terminate the previously announced letters of intent regarding Eureka Vapor and Tanforan Ventures LLC.  Mr. Justin Braune, President of Bonfire Brands USA will lead all NORTHBUD’s U.S. operations.

“Over the past seven months we have been working diligently to complete these transactions, however, during this time the market in California has evolved significantly,” said Ryan Brown, CEO of NORTHBUD.  “When the opportunity to purchase licensed real estate in one of the most desired cultivation climates in the state presented itself, we felt that this was the best strategy to maximize revenue as well as protecting shareholder value. The acquisition of this property will provide NORTHBUD with larger revenue potential and significantly less dilution than the previous proposed transactions. We look forward to a potential collaboration with both companies in the future and wish them the best of success.” 

The Nevada Botanical Science LOI agreement is still in place and the Company will update shareholders on material progress related to that transaction in due course.

While the proposed transactions involving Nevada Botanical Science and Monterey Holdings are complementary, they are independent and the Company may ultimately proceed to close one, both or none of the proposed transactions, depending on market conditions and regulatory requirements.

Corporate Update
NORTHBUD is pleased to update shareholders that the Evidence of Readiness Package was submitted to Health Canada and upon issuance of a standard cultivation licence from Health Canada, NORTHBUD will be ready to begin Canadian operations. 

About North Bud Farms Inc.
North Bud Farms Inc., through its wholly owned subsidiary GrowPros MMP Inc., is pursuing a licence under The Cannabis Act.  The Company has built a state-of-the-art purpose-built cannabis production facility located on 135 acres of Agricultural Land in Low, Quebec, Canada. NORTHBUD through its wholly owned U.S. subsidiary, Bonfire Brands USA has entered into agreements to acquire assets in California and Nevada.

For more information visit: www.northbud.com

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements and information included in this press release that, to the extent they are not historical fact, constitute forward-looking information or statements (collectively, “forward-looking statements”) within the meaning of applicable securities legislation.  Forward-looking statements, including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. This press release contains forward- looking statements including those relating to the entering into of the Definitive Agreement and closing of the Transaction with Qlora. Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the risk factors included in the Company’s final long form prospectus dated August 21, 2018, which is available under the Company’s SEDAR profile at www.sedar.com. Accordingly, readers should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statements to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]

Mark Wahlberg, Sean #Diddy Combs and Jillian Michaels Join the #CBD Craze – SPONSOR: NORTHBUD $NBUD.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 2:43 PM on Thursday, September 12th, 2019

SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

NBUD: CSE

Mark Wahlberg, Sean ‘Diddy’ Combs and Jillian Michaels Join the CBD Craze

By Peter Dalton

  • The Alkaline Water Company announced recently that it had acquired AQUAhydrate which is a Los Angeles-based bottled water producer.
  • Company is backed by Wahlberg, Sean “Diddy” Combs, and celebrity personal trainer Jillian Michaels.
  • This acquisition was part of plans to launch several CBD-infused products in the future.

There is a huge demand in different formats of CBD and there is increased popularity in functional wellness beverages. CBD is the non-psychoactive compound of cannabis. Many claim that CBD reduces pain and inflammation, helps with sleep, reduces anxiety, among many other medical needs.

The jury is still out, however, as the FDA states that those claims are unproven scientifically.Wahlberg, however, stated that he and Combs were excited by the acquisition as well as the opportunity to sell CBD products. Their vision was to build a lifestyles company focused on health and wellness. Wahlberg also believes that AQUAhydrate and Alkaline brands fit nicely together and will support future innovations in flavors, sparkling, and CBD products.

While Wahlberg is excited, he has spoken differently about marijuana in the past. He claimed to have stopped using marijuana due to his children. He also warned Justin Beiber “to lay off the grass”

Source: https://timesofcbd.com/mark-wahlberg-sean-diddy-combs-jillian-michaels-cbd-craze/

Spyder #Cannabis $SPDR.ca Enters into MOU with HighBreed Growth Corp. for a Proposed Reverse Takeover Transaction $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 10:58 AM on Thursday, September 12th, 2019
  • Signed a Memorandum of Understanding with HighBreed Growth Corp.
  • HBGC and Spyder Cannabis would be willing to complete a transaction that will result in a reverse take-over of Spyder Cannabis by HBGC
  • HighBreed Growth Ltd., is building a cannabis cultivation greenhouses facilities in Israel with a total planned size of 500,000 square feet.

Vaughan, Ontario–(Newsfile Corp. – September 12, 2019) – Spyder Cannabis Inc. (TSXV: SPDR) (“Spyder Cannabis” or the “Company“), an established Canadian cannabis accessory and vape retailer, is pleased to announce that it has signed a Memorandum of Understanding (the “MOU“) with HighBreed Growth Corp. (“HBGC“), that outlines the general terms and conditions pursuant to which HBGC and Spyder Cannabis would be willing to complete a transaction that will result in a reverse take-over of Spyder Cannabis by HBGC (the “Transaction“). The MOU was signed on September 5, 2019.

About HighBreed Growth Corp.

HBGC is a Canadian company located in Toronto, through its Israeli subsidiary HighBreed Growth Ltd., is building a cannabis cultivation greenhouses facilities in Israel with a total planned size of 500,000 square feet. HBGC has signed domestic sale contract with an entity to purchase its production capacity. The Israeli government announced that it would approve cannabis for export in 2019, and regulations are expected to be enacted in the 2nd quarter of 2020 to authorize export.

To strengthen its team, HBGC has reached an understanding to retain the services of a former chief agronomist of one for the largest, most experienced and world-renowned licensed producers in Israel.

About Spyder Cannabis

Founded in 2014 Spyder Cannabis is an established chain of five stores in Ontario, with locations in Woodbridge, Scarborough, Burlington, Pickering and Niagara Falls. The Spyder Cannabis brand is defined by its high-quality retail deals, dispensed in uniquely designed stores creating the optimal customer experience. Spyder Cannabis is building off this leading retail, distribution and branding company and is pursuing expansion into the legal cannabis and hemp derived market. Spyder Cannabis has developed a scalable retail model with plans to create a significant footprint with targeted and disciplined retail distribution strategy focusing on Canadian retail and U.S. boutique retail and kiosks in high traffic peripheral areas.

About the Transaction

The MOU is to be superseded by a definitive merger, amalgamation or share exchange agreement (the “Definitive Agreement“) that is expected to be signed on or prior to October 15, 2019, or such later date as may be mutually agreed upon by the parties in writing. The legal structure for the Transaction will be determined after the parties have considered all applicable tax, securities law and accounting factors. Completion of the Transaction is subject to a number of conditions, which include approval of the board of directors of each party, completion of mutual due diligence, the execution of the Definitive Agreement, receipt of all necessary securityholder and regulatory approvals, the delisting Spyder Cannabis’ common shares (the “Spyder Shares“) from the TSX Venture Exchange, the conditional approval of the listing of the Company on the Canadian Securities Exchange (the “CSE“), and the satisfaction or waiver of conditions to be set out in the Definitive Agreement.

Pursuant to the Transaction, the holders of common shares of HBGC (“HBGC Shares“) will receive common shares (“Resulting Issuer Shares“) of the entity resulting from the Transaction (the “Resulting Issuer“) in exchange for their HGBC Shares on the basis of an exchange ratio to be determined, but which is expected to result in the former shareholders of HGBC holding eighty percent (80%) of the Resulting Issuer Shares, with the remaining twenty percent (20%) of the Resulting Issuer Shares being held by the former shareholders of Spyder Cannabis without giving effect to the Financings (each as defined below). Following the completion of the Transaction, the Resulting Issuer will continue the businesses of HBGC and the Company.

The Transaction constitutes an Arm’s Length Transaction under the policies of the TSX Venture Exchange.

An application will be made to voluntarily delist the Spyder Shares from the TSX Venture Exchange and to list the Resulting Issuer Shares on the CSE. The delisting of the Company from the TSX Venture Exchange and the listing of the Resulting Issuer on the CSE will be subject to all applicable shareholder and regulatory approvals.

In connection with the Transaction, the parties intend to complete one or more private placements to pay for, among other things, the expenses of the Transaction and to provide working capital pending completion of the Transaction (the “Financings“). The terms of the Financings including the securities offered, the size of the Financings and the issue price per security will be determined in the context of the market by negotiation between HBGC, the Company, and any applicable investment dealer.

Further details of the Transaction and the business and operations of the Resulting Issuer (including applicable financial statements) will be included in a listing statement to be prepared and filed with the CSE, and in subsequent news releases and other public filings. Trading in the Spyder Shares on the TSX Venture Exchange will remain halted until all necessary filings have been accepted by applicable regulatory authorities.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Spyder Cannabis Inc.
Dan Pelchovitz
President & Chief Executive Officer
Contact: Investor Relations
Phone: 1-888-504-SPDR (1-888-504-7737)
Email: [email protected]

Bullseye Corporate
Crystal Quast
Bullseye Corporate
[email protected]

HighBreed Growth Corp.
Patrick Gregory
Executive Chairman
Phone: 905-818-0725
Email: [email protected]

Empower Clinics $CBDT.ca Subsidiary Sun Valley Health Exhibits at the Chicago Franchise Show and Provides Corporate Update Highlighting Double Digit Patient Growth $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 8:25 AM on Thursday, September 12th, 2019
  • Double Digit Patient Growth
  • Company continues to see patient visits in corporate clinics increase by double digits, with July 2019 patients seen increasing by 42% to 1,817 over July 2018, and August 2019 patients seen increasing by 39% to 2,099.
  • Historically, summer months are seasonally slower and the Company anticipates continued double-digit growth in the patients seen count going forward.

VANCOUVER, Sept. 12, 2019 /CNW/ - EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, a multi-state operator of medical health & wellness clinics, a CBD product producer and operator of an extraction facility in Oregon, is pleased to announce it is participating as a marquee exhibitor in the Chicago Franchise Show https://www.franchiseexpochicago.com September 13th & 14th, 2019.

Franchise Expo Chicago (FEC) is the premier event covering the franchise industry for the Greater Chicago Area, and serves as the industry’s one-stop shop for prospective franchisees. Thousands of entrepreneurs and future business owners from across the United States will attend Franchise Expo Chicago, looking for franchise opportunities.

“Attending Franchise Expo Chicago (FEC) puts Sun Valley Health in front of potentially thousands of entrepreneurs looking for a turnkey and progressive business opportunity,” said Steven McAuley, CEO of Empower. “The combination of offering health & wellness services with premium CBD products lines and wellness products are in high demand, and we believe Sun Valley Health can be the market leader.”

HIGHLIGHTS

  • Double Digit Patient Growth The Company continues to see patient visits in corporate clinics increase by double digits, with July 2019 patients seen increasing by 42% to 1,817 over July 2018, and August 2019 patients seen increasing by 39% to 2,099. Historically, summer months are seasonally slower and the Company anticipates continued double-digit growth in the patients seen count going forward.

  • Retail Product Kiosks The Company has completed the set up of its full retail product kiosks and display areas in its key Phoenix clinics, with over (40) product SKU’s, including the CBD lines of Sollievo, Sun Valley Science and a variety of premium health supplements.

  • Extraction Facility Progress The Company has been awarded its hemp-handlers license from the Oregon Department of Agriculture, and now are approved to operate the new 5,000 sq. ft. facility in Sandy, OR. Pathangay Architects have been retained to complete the design and drawings, to submit permit approvals that commence the next phase of build-out. Security systems and IT networks have been installed.

  • Hemp Bio-Mass Supply The Company has commenced RFP’s (Request For Proposal’s) to access the more than 1,300 licensed hemp famers in the State of Oregon, that are known to produce some of the highest quality hemp bio-mass in the United States.

  • CBD Market Demand The passing in the United States of the US$867 billion Agriculture Improvement Act (the “Farm Bill“) has legalized hemp and hemp-based products. This has created an opportunity for the production and sale of a variety of CBD-based products that can provide genuine help and effective relief to millions of people suffering from a variety of qualifying conditions. Recent reports and studies indicate the approval of the Farm Bill could create a US$20 billion industry by 2022

  • Sun Valley Health Franchise Sun Valley Health www.sunvalleyhealth.com offers a scientific approach to alternative medicine supported by a network of ten (10) corporate locations and a nationwide franchise program that offers a turnkey opportunity including:
  • An electronic medical system that handles patient data and sensitive information, and deals with program tracking, referrals, and appointment reminders
  • A proven operational system that has 165,000 patients in its database
  • A retail CBD and premium wellness product offer to diversify and attract customers
  • An industry leading campaign management system using text messaging, email and call center systems to engage patients and customers
  • Paperless communication channels that are HIPAA compliant
  • On-site and web-based training systems to develop franchisees
  • Sophisticated advertising programs proven to connect with local customers
  • Support and infrastructure to ensure franchisees have a formula for success

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the terms of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that the hemp-based CBD extraction facility may not be fully operation by Q2 2019 if at all; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2019/12/c9443.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019

A #Cannabis Pioneer with Strong Value & Upside Potential – NORTHBUD $NBUD.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 2:27 PM on Wednesday, September 11th, 2019

If there’s one thing investors don’t like, its surprises with their stocks. A nice easy story is often elusive, but when it appears, it should be noted for the value it offers.

That’s the theme behind Canadian cannabis producer NORTH BUD Farms Inc. (CSE: NBUD, OTCQB:NOBDF, Forum). At a time when the industry is looking to “Legalization 2.0” as an incoming wave of new cannabis-infused products, there is also a new type of cannabis company emerging. In this case, with NBUD, it boasts the merit of being one of the very lowest market caps of any cannabis operator on the Canadian Securities Exchange at around $15 million as of early September 2019.

Trading at less than 1X its 2020 projected revenue in Canada alone, the Company is one of the most reasonably-priced operators. Its chief asset: A purpose-built facility with projected yields and revenues coming down the pipeline next year. As a one-off Canadian licensed producer (LP), it offers a clean prospect. In an interview talking about his Company with Stockhouse Editorial, CEO Ryan Brown described the mindset behind NORTHBUD brand:

“Every time someone buys a NORTHBUD product, I want them to feel like they bought a case of Heineken and they paid the price of Budweiser for it.”

CEO Brown laid out the Company’s strategy through three questions that help define NBUD’s goals:

  • Who is our audience?
  • What do they consume?
  • What do they have to build to efficiently and cost-effectively produce those products for that consumer?

As covered in an August 2019 feature article on Stockhouse and its recent coprorate update video, NORTHBUD has completed construction of its 24,500 square foot Phase One indoor cannabis cultivation facility located on 135 acres of land in Low, Québec. The Company is also looking to use part of its outdoor crop for pharmaceutical and food-grade cannabis applications. More on this facility later.


(NORTHBUD facility.)

Growing Market Opportunity:

Share prices among cannabis companies have been hit hard, but that doesn’t mean the industry is going away. The next opportunity is still out there. As we approach a year post-legalization in Canada, the risk / reward scenario for a lot of operators looks much clearer.

With NORTHBUD, the Company presents rewards that are quite tangible when looking at the grand scheme of investing in cannabis, with really no greater risk than any other company. While other operators struggle to meet demand for products, this is a clean operator with a straightforward story about a stock moving quickly in a green direction, rather than into the red.

The “2.0” philosophy is about more than just legalizing a new type of cannabis product or greater availability for dried flower, but it is also about new company structure, how they’re built-out, financed and how this shapes their market caps. An investor doesn’t have to look very far to find a licensed cannabis company of a comparable size to NBUD trading at even 2.5 – 3.5X their market value, but this is where the Company’s upside comes from. With other players in the field, there are often some “unlocks” with their shares that can take an investor by surprise. Since NBUD listed in September 2018, all of its shares are left on the table, basically unlocked, there’s no “Acreage scenario” where traders invest early and get slammed by insider unlocks. Company leadership took this into consideration when it decided to go public and is still trading around its IPO issue price in a tense market, which indicate it is on the right path from a business and investment perspective. An investor knows exactly what they are getting.

Product Timeline:

NORTHBUD is looking at a 2020 rollout for the release of its brand of flower to the market, which will be available as dried flower and pre-roll products. As a consumer-facing brand, its focus will be on a market demographic within the existing consumer base that is not currently buying from the legal market. The target is the 80% of consumers who go for “grey” and “white” market suppliers, which has been estimated to be worth roughly $3 billion, according to cannabis business accelerator Grow Tech Labs.

How NORTHBUD intends to penetrate that market, is by ensuring it always has a very favourable cost-to-value ratio. The Heineken quality for Budweiser price philosophy, at a time when many other companies are focused on premium products or the cheapest product in the biggest growing space, when a large portion of the market is looking for something else.

Facility:

NORTHBUD completed its Phase One indoor cannabis cultivation facility in August 2019 and submitted the facility’s Evidence of Readiness Package to Health Canada. As soon as shovels went into the ground, CEO Brown stated that efficiency and productivity were the main objectives when building this facility.

The objective here wasn’t to shove as much growth space into the building as possible, nor was it to make a claim that it has X-amount of growth space, just focus on tangible size for a Phase One project in a manner that would be conductive to producing good quality products.

What makes this project unique, is that it is built on a large piece of agricultural land, much larger than what is required for the Company’s operations now. It is currently using more than adequate space to produce a significant number of clones, while also being ready for outdoor planting come spring 2020. Instead of cramming the facility full of as much equipment as possible at the expense if workflow and employee comfort, NORTHBUD left room to expand and grow. This is a different approach for a cannabis operator, designing a functional production facility for a Company of this size.

Another benefit that should not be overlooked is the facility’s location, situated near the second largest hydroelectric dam in Québec. The Company strategically positioned its operation here to harness the low-cost advantages the province has over anywhere else in Canada.

Unlike other operators in the “1.0” cannabis phase who just wanted to get a building licensed and run a profitable company, NORTHBUD looked to the future and decided to place their facility in a rural setting before work began. Others are now looking for cheaper plots of land in rural settings as their urban operations have become too expensive to run.

CEO Brown noted that the facility was built to Good Manufacturing Practice (GMP) standards, even though the Company has not applied to that certification but wanted to be following that standard with brand new, state-of-the-art equipment. From the start, the thought process was to build the facility with the target consumer in mind in the most economical way possible.


(Image via NORTHBUD Corporate update video.)

Company History:

Founded in June 2018 as a division of NORTHBUD Capital Holdings Ltd. (which is also one of the the Company’s largest investors), NBUD acquired a late-stage Access to Cannabis for Medical Purposes Regulations (ACMPR) application from Tetra Bio-Pharma Inc. (TSX: V.TBP). At the time, it was believed that there was value in legacy applications and if there was going to be any shakeups in the way Health Canada process the applications, NORTHBUD would be insulated by acquiring that application early, rather than starting from scratch. Since the federal government did just that when it put the Cannabis Act ahead and amended the criminal code, it was a solid plan in hindsight.

This legacy application was the start of the Company’s focus on efficient operations, as it provided the best environment to move forward in what has been considered a rather risky industry. The approach added security for both NORTHBUD but also its investors.

NORTHBUD raised capital through a variety of financing rounds, including an IPO at $0.25 cents a share and began construction at its facility.

CEO Brown was intrigued by the project while he was at Tetra. He has experience as an investor in cannabis and felt like he could offer a lot to building the Company and its brand, as opposed to solely focusing on investing into it. Now he comes back full-circle as an operator in this space, helping to grow the Company.


(NORTHBUD facility, aerial view.)

With an eye to close more deals in the near future, NORTHBUD is continuing to build its footprint across what it sees as the four largest markets in North America.

  • California – The largest cannabis market (expected to reach $3.1 billion in 2019 sales)
  • Nevada – Boasting a massive tourist advantage, the state has a high retail price, but devoid of a black-market supply
  • Canada – Estimated to be worth $5 billion by 2021

Investment Conclusion:

NORTHBUD Farms’ chief intent is to make sure its customers feel like they get more value out of these products than the money they spent. The customers will come to know what the brand feels like. This is how a legacy following is built – the type of consumer who knows what they are buying before they make that purchase.

These metrics are more straightforward to measure now that we approach a year’s worth of legal sales and can see where the sweet spots in the market exist. This is where NORTHBUD has targeted to operate.

The Company is run by individuals who are cannabis industry experts, not high tech or CPG types. They come from the cannabis industry and see this as their opportunity to be involved in bringing a successful Company to market, build a brand and get behind it. By the cannabis consumer for the cannabis consumer.

Source: http://whatcounts.com/dm?id=74EF17FF1FEB9C7D4164FE30F55E9FBE4B93FB24D3F3D6A0

Spyder #Cannabis $SPDR.ca – New Report Puts North American Cannabis Market At $47.3B By 2024 $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 7:02 AM on Friday, September 6th, 2019

SPONSOR: Spyder Cannabis (SPDR:TSXV) An established chain of high-end vape stores. Aggressive expansion plan is already in place that will focus on Canadian retail and US Hemp derived kiosks in high traffic areas. Click here for more info.

(TSX-V: SPDR)

New Report Puts North American Cannabis Market At $47.3B By 2024

  • Market research and data analytics firm Prohibition Partners has released its first North American Cannabis Report.
  • The firm is estimating that by 2024, the continent’s cannabis market will be worth $47.3 Billion.
  • Big-name brands entering the game and celebrity endorsements are cited as important steps toward positioning cannabis as a mainstream product.

In the 134-page paper, the firm analyzes the current state of the cannabis industry in Canada and the United States to draw key insights into the industry’s future in the region.

The firm is estimating that by 2024, the continent’s cannabis market will be worth $47.3 Billion.

Daragh Anglim, the firm’s managing director, said the report offers good reason to believe that both medical and recreational cannabis will be completely legal in the entire region by that same year and â€œintegrated across a number of industry verticals from pharma to food.”

Key Insights

Although the report places Canada as a global leader and an example for countries looking to follow suit with cannabis legalization, it also said the U.S. could soon challenge its northern neighbor’s leadership.

Federal legalization could turn the scale around for the two countries.

Big-name brands entering the game and celebrity endorsements are cited as important steps toward positioning cannabis as a mainstream product.

A long-term decline in smoking and a stagnation in alcohol consumption are helping the cannabis sector accelerate through Big Tobacco and Big Alcohol investments and alliances, which are expected to continue to flourish, according to Prohibition Partners. 

The cannabis industry is expanding within the beauty market, with many premium retailers offering cannabis products.

The edible revolution is expected to hit big, with great expectations around Canada’s legalization of cannabis edibles next month. 

Publicly Listed Cannabis Companies

The number of cannabis companies listed on stock exchanges has increased substantially.

The CSE is by far the largest lister for cannabis companies, with 156.

Curaleaf (OTC: CURLF), Green Thumb Industries (OTC: GTBIF), Cresco Labs (OTC: CRLBF), Acreage Holdings (OTC: ACRGF) and Harvest Health & Recreation (OTC: HRVSF) top the CSE’s list in terms of market cap.

The TSX follows with 22 listed companies; NASDAQ with 15; and NYSE with nine, where the leaders in terms of market cap are Canopy Growth (NYSE: CGC), Aurora Cannabis (NYSE: ABC), The Scotts Miracle-Gro Company (NYSE: SMG), Aphria (NYSE: APHA) and Hexo Corp. (NYSE: HEXO). 

Current, Projected Cannabis Market Values

The estimated value for medicinal cannabis in both Canada and the U.S. today is of $10.6 billion, and that figure is expected to climb to $25.2 billion by 2024, the North American Cannabis Report said.

The recreational market is estimated at $6.5 billion, with a climb to $22.1 billion projected in five years. Both markets are projected to climb to a cumulative $47.3 billion in 2024, which would represent 177% growth.

Cannabis Consumers: Key Insights

In both countries, 22% of the population reported having consumed cannabis within the past 12 months.

In the U.S., 19% of users said they use cannabis products to relieve pain. In Canada, the average age of first-time consumption is almost 19 years old.

Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago

Source: https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/report-puts-north-american-cannabis-160855123.html